Qualigen Therapeutics to Acquire Majority Stake in Diagnostics Technology Company NanoSynex
May 03, 2022 09:17 ET
|
Qualigen Therapeutics, Inc.
Companies to Collaborate in the Development of Innovative Diagnostics Platform to Combat “Superbugs,” a Rising Global Health Crisis CARLSBAD, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Qualigen...
OpGen Presents Preliminary Acuitas® AMR Gene Panel Data for Detecting Urinary Tract Infections
October 07, 2019 07:30 ET
|
OpGen, Inc.
GAITHERSBURG, Md., Oct. 07, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) today announced the presentation of preliminary data at IDWeek 2019 for the Company’s Acuitas® AMR Gene Panel and...
OpGen Provides update on Curetis Group’s R&D Collaboration
September 18, 2019 07:30 ET
|
OpGen, Inc.
Curetis R&D collaboration to develop NGS-based predictive antibiotic resistance testing powered by ARESdbCollaborator to fund R&D and obtains option to license ARESdb and ARES Technology...
OpGen Announces New Data Demonstrating Clinical Utility for Antibiotic Resistant Urinary Tract Infection Patient Management and for Rapid Carbapenem-Resistant Bacteria Outbreak Detection
June 13, 2019 07:30 ET
|
OpGen, Inc.
GAITHERSBURG, Md., June 13, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today that data from its Acuitas® AMR Gene Panel and Acuitas Lighthouse® Software will be presented at ASM...
OpGen Completes Initial FDA 510(k) Submission for its Acuitas® AMR Gene Panel Test to Identify Presence of Antibiotic Resistance
May 14, 2019 07:30 ET
|
OpGen, Inc.
GAITHERSBURG, Md., May 14, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today that it has filed its 510(k) submission with the U.S. Food and Drug Administration (FDA) for clearance...
Global charity discovers superbugs in pork products
December 19, 2018 08:00 ET
|
World Animal Protection
Toronto, ON, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Bacteria that is resistant to antibiotics most critically important to humans, has been found in pork from supermarket shelves in Brazil, Spain and...
SpeeDx Receives CE-IVD Mark for ResistancePlus® GC Gonorrhea Test
December 06, 2018 03:30 ET
|
SpeeDx Pty Ltd
SYDNEY, Australia, Dec. 06, 2018 (GLOBE NEWSWIRE) -- SpeeDx Pty. Ltd. announced today it has received CE-IVD marking for its ResistancePlus® GC assay that detects both the sexually transmitted...
Melinta Therapeutics Presenting Results from Baxdela and ESKAPE Programs at ASM Microbe 2016 Meeting
June 14, 2016 12:30 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, June 14, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced that...
Melinta Therapeutics Study Demonstrates Significant Burden of Obesity on Patients' Recovery from Acute Bacterial Skin Infections
May 19, 2015 16:00 ET
|
Melinta Therapeutics
New Haven, CT, May 19, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics today presented data that show the negative
impact of obesity on patients' recovery from acute bacterial skin
and skin structure...
Melinta Therapeutics Shows that Health-Related Quality-of-Life is higher in ABSSSI Patients Deemed Cured vs Improved after End of Treatment
April 09, 2015 12:02 ET
|
Melinta Therapeutics
New Haven, CT, April 9, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics today presented an evaluation of
Health-Related Quality-of-Life (HRQL) in acute bacterial skin and
skin structure infection...